Sign in
Taking people in United StatesNo phase

Continuous Glucose Monitoring Device Tested in Adults With Type 2 Diabetes

Tests a glucose monitoring device in adults with type 2 diabetes who take daily insulin.

Key facts

Who runs it
Tulane University
Where
New Orleans, United StatesSee the site
Trial code
Registry title
Continuous Glucose Monitoring (CGM) in an Underserved Population
Status
Recruiting
People taking part
50 people, planned
Started
19 Mar 2026
Expected to end
Jul 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Continuous Glucose Monitoring (CGM)
Record updated
5 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes who take at least one insulin injection a day. They must be uninsured or on Medicaid and use clinics in the New Orleans area.

Age
18 to 75 years
Sex
Men and women
Disease stage
Type 2 diabetes with HbA1C of 7.5% (58 mmol/mol) or higher
Earlier treatment
At least 1 insulin injection every day. People already using CGM or an insulin pump cannot join.
Biomarker or test result
HbA1C of 7.5% (58 mmol/mol) or higher

Main reasons for not taking part

  • Type 1 diabetes
  • Already using CGM or an insulin pump
  • Advanced kidney disease or eGFR below 40
  • End-stage kidney disease, dialysis or a kidney transplant
  • Pregnant

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Age 18-75 years
  • Type 2 diabetes mellitus
  • HbA1C ≥ 7.5%
  • At least on 1 insulin injection therapy daily
  • Patients established with primary care clinic or endocrinology clinic or diabetes clinics in the New Orleans and surrounding areas
  • Patients with Medicaid or free care or uninsured
  • Patients must be able to speak and understand English and be capable of providing informed consent to participate in the study

Who cannot take part

  • Currently on CGM or using insulin pump
  • Type 1 diabetes mellitus
  • Advanced renal disease or Estimated Glomerular Filtration Rate (eGFR) <40
  • The patient has been diagnosed with end-stage renal disease, is on dialysis, or has had a kidney transplant, Hemoglobinopathies, iron therapy or other condition that interferes with HbA1c measurement
  • Serious co-morbidities which in the investigator's opinion, will make it challenging for patients to participate
  • Pregnant

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • University Medical CenterNew Orleans, United StatesContact: Neha Upadhyay, BDS,MPHTaking people

About the trial

What the trial wants to find out

The investigators aim is to conduct a randomized clinical trial in an underserved population who are either uninsured or on Medicaid and taking at least one injection of insulin daily. The investigators believe that this study will lead to considerable alleviation of health disparities and provide better care for an underserved population. This will be a pilot study to evaluate the feasibility of such a trial in this population before doing a larger multicenter trial.

The 2 groups in the trial

  • Self-Monitoring of Blood Glucose (SMBG)Placebo, for comparison

    The study participants will be randomized to the self-monitoring group (control) after a period of two-week run-in and followed for 6 months. They will be given an opportunity to wear the CGM sensor for 3 months at the conclusion of the 6-month follow-up as an optional follow-up.

    Treatment: Continuous Glucose Monitoring (CGM)

  • Continuous Glucose Monitoring (CGM)Existing treatment, for comparison

    The study participants will be randomized to the continuous glucose monitoring group (intervention).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Continuous Glucose Monitoring in an Underserved Population: Impact on Glucose Control, Patient Reported Outcomes, Healthcare Utilization, and Long Term Complications
Plain-language title
Continuous Glucose Monitoring Device Tested in Adults With Type 2 DiabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07135531, who can take part
Record updated
5 May 2026